ISPOR - Is Obinituzumab the most Cost-Effective Biological Therapy for Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia in Colombia?

Full Text

Is Obinituzumab the most Cost-Effective Biological Therapy for Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia in Colombia?

Abstract

Authors

SA Saenz Ariza

Back to Volume 19, Issue 3

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now